- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00930332
Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain
A Phase I Study to Determine the Dose of Methadone as a First Line Agent in the Treatment of Chronic Neuropathic Cancer Pain
RATIONALE: Methadone hydrochloride may reduce chronic neuropathic pain in patients with cancer.
PURPOSE: This phase I trial is studying the side effects and best dose of methadone hydrochloride as first-line therapy in treating patients with chronic neuropathic cancer pain.
Study Overview
Status
Conditions
Detailed Description
OBJECTIVES:
Primary
- To determine the optimum starting dose (defined as the dose that does not require modification within the first 4 days of treatment for lack of efficacy or the occurrence of adverse events) of methadone hydrochloride as a first-line opioid treatment in patients with chronic neuropathic cancer pain.
Secondary
- To assess the number and timing of breakthrough analgesic usage.
- To assess the number of episodes of breakthrough pain.
- To assess the total daily dose of methadone hydrochloride.
- To assess the average pain score.
- To determine the safety and adverse event profile of methadone hydrochloride as a first-line opioid in the treatment of chronic neuropathic cancer pain.
- To assess the frequency and severity of sleep disturbance associated with the use of methadone hydrochloride.
- To determine the feasibility of recruiting patients with chronic neuropathic cancer pain in a reasonable time frame for a future phase III study of methadone hydrochloride vs morphine.
OUTLINE: This is a multicenter study. Patients are assigned to a group according to their average daily dosage of morphine-equivalent for the 3 full days prior to study entry (≤ 45 mg/day OR > 45 but ≤ 75 mg/day).
Patients receive oral methadone hydrochloride at various doses every 8 hours. Patients also may receive breakthrough oral methadone hydrochloride every 2 hours, as needed, for up to 6 breakthrough analgesics per day. Treatment continues for up to 35 days. Treatment stops if the patient has well-controlled pain or experiences intolerable side effects.
Patients complete the Short-Form McGill Pain Questionnaire at baseline. Patients rate their pain according to questions from the Brief Pain Inventory on a scale of 0 (no pain) to 10 (worst pain imaginable) to best describe pain at its worst in the last 24 hours, pain at its least in the last 24 hours, pain on average, and pain right now; record the number and timing of breakthrough analgesic usage, the number of episodes of breakthrough pain, and the total daily dose of methadone hydrochloride; and complete nausea and sleep assessments once daily on days 1-14.
After completion of study treatment, patients are followed at 4, 6-7, and 28 days.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 5L3
- BCCA - Cancer Centre for the Southern Interior
-
Vancouver, British Columbia, Canada, V5Z 4E6
- BCCA - Vancouver Cancer Centre
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 5P9
- Cancer Centre of Southeastern Ontario at Kingston
-
Toronto, Ontario, Canada, M5G 2M9
- Univ. Health Network-Princess Margaret Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H2W 1S6
- McGill University - Dept. Oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
DISEASE CHARACTERISTICS:
Patients diagnosed with cancer and experiencing chronic neuropathic pain syndrome
- Pain syndrome diagnosed by the investigator
- Pain syndrome related to the effects of cancer or its treatment (i.e., chemotherapy, radiotherapy, and surgery)
Meets 1 of the following criteria:
- Need to be started on strong opioids
- Require an increase in opioid dose and are currently taking ≤ 75 mg of total daily dose of oral morphine equivalent
- Experiencing pain for ≥ 4 weeks with an average pain score of ≥ 4 or a worst pain score of ≥ 5 (using the 0-10 Brief Pain Inventory Scale) during the past 24 hours
- Requires strong opioids to control pain and is using an oral morphine-equivalent dose of 0-75 mg per day, on average, including breakthrough analgesia, within the past 3 full calendar days
- Mixed pain syndrome allowed provided the neuropathic component is the predominant pain
Meets 1 of the following criteria:
- Receiving concurrent chemotherapy but the chronic neuropathic pain is not related to this treatment and is not expected to improve or worsen because of this therapy
- Received prior chemotherapy but discontinued treatment, has not received chemotherapy within the past 7 days, and no further chemotherapy is planned
- No prior chemotherapy
PATIENT CHARACTERISTICS:
- Karnofsky performance status 40-100%
- ALT and AST ≤ 3 times upper limit of normal (ULN)
- Creatinine ≤ 2 times ULN
- No other known laboratory abnormality that, in the investigator's opinion, would contraindicate study participation
- Not pregnant or nursing
- Fertile patients must use effective contraception
- Mini-Mental State Examination score ≥ 25/30
- Able to speak, read, and write in either English or French
- Willing to complete study diary and questionnaires
- Available for study treatment and follow up (i.e., within reasonable geographical limits of the participating center)
- Able to swallow and tolerate oral medications
- Patients with prior exposure to methadone hydrochloride must be able to tolerate it
- No intractable nausea and vomiting
No presence or history of unstable disease or condition that would, in the investigator's opinion, preclude patient participation in study treatment, such as:
- Head injury
- Increased intracranial pressure
- Uncontrolled seizures
- Uncontrolled asthma
- Decompensated chronic obstructive pulmonary disease
- Untreated prostate hypertrophy
- Acute abdominal conditions
- Untreated hyperthyroidism and Addison disease
- Increased cerebrospinal fluid pressure
- Urethral stricture
- Severe cardiac arrhythmias (especially prolonged QT interval)
- Symptomatic hypotension
- Toxic psychosis
- Cor pulmonale
- Sleep apnea
- Severe obesity
- Kyphoscoliosis
- Myxedema
- Central nervous system depression
- Coma
- No history of significant alcohol, analgesic, or narcotic substance abuse within the past 6 months
- Able physically and mentally to answer questions and comply with study treatment
- No patient who lives alone and cannot access at least 1 caregiver who can monitor on a daily basis at home
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 3 weeks since prior radiopharmaceutical treatment or radiotherapy
- Concurrent co-analgesics and medications that can affect methadone hydrochloride metabolism allowed provided patients have been on a stable dose for the past 3-5 days and ≥ 5 half lives have passed since any change in dose
- Not scheduled to start chemotherapy during the study treatment
- Not planning on starting or discontinuing medication associated with modified methadone hydrochloride clearance during study treatment
- No concurrent therapeutic procedure that is likely to influence pain intensity during the study period
- No concurrent other opioid medications
- No other concurrent methadone hydrochloride
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm A: Methadone
Level 1: 1 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA** per day) Level 2: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) Level 3: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) |
Level 1: 1 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA** per day) Level 2: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) Level 3: 3mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) OR Level 1: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) Level 2: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) Level 3: 4 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)
within 48 hours of registration
if required
|
Active Comparator: Arm B: Methadone
Level 1: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) Level 2: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) Level 3: 4 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) |
Level 1: 1 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA** per day) Level 2: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) Level 3: 3mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) OR Level 1: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) Level 2: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) Level 3: 4 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)
within 48 hours of registration
if required
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Optimum starting dose
Time Frame: 28 days
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pain control as assessed by the number and timing of breakthrough analgesics, the number of episodes of breakthrough pain, the total daily dose of methadone, and the average pain scores
Time Frame: 28 days
|
28 days
|
Adverse events (including respiratory depression) according to NCI CTCAE v3.0 criteria
Time Frame: 28 days
|
28 days
|
Frequency and severity of sleep disturbance from pain
Time Frame: 28 days
|
28 days
|
Feasibility of recruiting patients
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Bruno Gagnon, MD, MSC, McGill Cancer Centre at McGill University
- Study Chair: Ray Viola, Queen's University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Signs and Symptoms, Digestive
- Nausea
- Vomiting
- Sleep Wake Disorders
- Parasomnias
- Cancer Pain
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Respiratory System Agents
- Antitussive Agents
- Methadone
Other Study ID Numbers
- SC22
- CAN-NCIC-SC22 (Registry Identifier: PDQ)
- CDR0000641372 (Other Identifier: PDQ)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
Cairo UniversityCompletedCervical Pain | Lumbar Pain SyndromeEgypt
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
Clinical Trials on methadone hydrochloride
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedPain | Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative...United States
-
Mayo ClinicTerminated
-
Pontificia Universidad Catolica de ChileCompletedPain, Postoperative | Opioid Use | Methadone Overdose of Undetermined IntentChile
-
Children's Hospital Medical Center, CincinnatiEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedNeonatal Abstinence SyndromeUnited States
-
Universidade Federal de Santa MariaHospital de Clinicas de Porto Alegre; Santa Casa de Misericórdia de Belo HorizonteCompleted
-
University of AarhusTerminatedPain, Postoperative | Pain, Acute | Children, OnlyDenmark
-
Kanecia Obie ZimmermanCompleted
-
University of Southern DenmarkRecruitingHip Fractures | MethadoneDenmark
-
University Hospital, Clermont-FerrandCSAPA ANPAA 63UnknownOpiate Dependent | Previous Illicit Drug UseFrance